GRI BIO INC(GRI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GRI GRI BIO INC

交易中 06-03 10:04:22 EDT

2.01

-0.02

-0.98%

最高2.06	最低2.00	成交量2,868
今开2.00	昨收2.03	日振幅2.96%
总市值355.96万	流通市值99.20万	总股本177.08万
成交额5,843	换手率0.58%	流通股本49.35万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GRI","market":"US","secType":"STK","nameCN":"GRI BIO INC","latestPrice":2.0101,"timestamp":1780495302633,"preClose":2.03,"halted":0,"volume":2868,"delay":0,"changeRate":-0.009802955665024536,"floatShares":493500,"shares":1770838,"eps":-87.4667,"marketStatus":"交易中","change":-0.0199,"latestTime":"06-03 10:04:22 EDT","open":2,"high":2.06,"low":2,"amount":5843.0340468,"amplitude":0.029557,"askPrice":2.06,"askSize":200,"bidPrice":2.01,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-87.4667,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780516800000},"marketStatusCode":2,"symbolChange":{"newSymbol":"RDOG","executeDate":"2020-01-02"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.03,"sharesOutstanding":1100000,"nav":47.93,"aum":52503274.57,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":2.07,"preClose":2.03,"latestTime":"08:42 EDT","volume":52,"amount":107.1827068,"timestamp":1780490526264,"change":0.04,"changeRate":0.019704,"amplitude":0.034483},"postHourTrading":{"tag":"盘后","latestPrice":2.0781,"preClose":2.01,"latestTime":"19:59 EDT","volume":525,"amount":1085.2142,"timestamp":1780444778074,"change":0.0681,"changeRate":0.033881,"amplitude":0.034677},"volumeRatio":0.674666},"requestUrl":"/m/hq/s/GRI","defaultTab":"news","newsList":[{"id":"2636781133","title":"吕建中：中国企业从“增长逻辑”走向“共生逻辑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2636781133","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636781133?lang=zh_cn&edition=full","pubTime":"2026-05-20 15:35","pubTimestamp":1779262500,"startTime":"0","endTime":"0","summary":"　　吕建中在演讲中指出，今天是“520”，一个关于爱与承诺的日子，这一天，也是“可持续社会价值生态圈”倡议设立的“企业公益日”。　　“而在这一过程中，我们也看到越来越多中国企业，开始从‘增长逻辑’走向‘共生逻辑’，从单一财务价值，走向商业价值、社会价值、环境价值的融合统一。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-05-20/doc-inhyptae2549109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","GRI","BK4139","SINA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616852325","title":"Gri Bio, Inc.盘中异动 早盘股价大跌5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616852325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616852325?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:30","pubTimestamp":1772461831,"startTime":"0","endTime":"0","summary":"北京时间2026年03月02日22时30分，Gri Bio, Inc.股票出现波动，股价大幅跳水5.49%。Gri Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Gri Bio, Inc.公司简介：GRI Bio Inc是一家临床阶段的生物技术公司，专注于发现、开发和商业化针对与免疫反应失调相关的严重疾病的疗法，这些疾病包括炎症、纤维化和自身免疫性疾病。GRI Bio的项目GRI-0621是一种小分子RAR-beta和gamma双重激动剂，能抑制人类NKT I细胞的活性，使免疫系统恢复到稳态。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603022230319542a15c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603022230319542a15c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GRI","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610646634","title":"Gri Bio, Inc.盘中异动 急速下挫7.53%报2.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610646634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610646634?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:39","pubTimestamp":1770647957,"startTime":"0","endTime":"0","summary":"北京时间2026年02月09日22时39分，Gri Bio, Inc.股票出现异动，股价快速下跌7.53%。Gri Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Gri Bio, Inc.公司简介：GRI Bio Inc是一家临床阶段的生物技术公司，专注于发现、开发和商业化针对与免疫反应失调相关的严重疾病的疗法，这些疾病包括炎症、纤维化和自身免疫性疾病。GRI Bio的项目GRI-0621是一种小分子RAR-beta和gamma双重激动剂，能抑制人类NKT I细胞的活性，使免疫系统恢复到稳态。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209223917a6e69302&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209223917a6e69302&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GRI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182684414","title":"GRI BIO INC重申2025财年全年业绩，强化资产负债表，并概述近期关键进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1182684414","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182684414?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:46","pubTimestamp":1770212773,"startTime":"0","endTime":"0","summary":"GRI BIO INC已正式重申其2025财年全年财务业绩，同时通过优化资本结构显著强化了公司资产负债表。此外，管理层还系统梳理并总结了近期在业务运营、研发进展及战略合作等方面的关键亮点，展现出公司在复杂市场环境中的稳健态势与成长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133623721","title":"GRI BIO INC公布引人注目的2a期新基因表达数据 显示特发性肺纤维化关键驱动因子及肺修复指标改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1133623721","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133623721?lang=zh_cn&edition=full","pubTime":"2026-01-28 21:47","pubTimestamp":1769608025,"startTime":"0","endTime":"0","summary":"GRI BIO INC最新发布的2a期临床试验基因表达数据取得突破性进展，该数据清晰表明在特发性肺纤维化治疗中，与纤维化进程和肺部组织修复相关的核心生物标志物呈现显著积极变化。研究结果揭示了实验疗法对疾病关键通路的影响，为后续临床开发提供了强有力的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177458457","title":"GRI Bio Inc：GRI-0621持续展现卓越特性，兼具良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1177458457","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177458457?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:05","pubTimestamp":1767877514,"startTime":"0","endTime":"0","summary":"GRI Bio Inc旗下在研药物GRI-0621的最新数据持续展现出引人瞩目的综合特性。该药物在临床前及早期临床研究中，不仅表现出良好的安全性特征，其耐受性结果也同样令人鼓舞。这种将优异安全性与可接受耐受性相结合的特点，为GRI-0621的后续开发奠定了坚实基础，凸显了其作为潜在疗法的独特优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113953690","title":"GRI Bio公布IPF二期a期研究新增积极数据，强化GRI-0621临床概念验证","url":"https://stock-news.laohu8.com/highlight/detail?id=1113953690","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113953690?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:05","pubTimestamp":1767877510,"startTime":"0","endTime":"0","summary":"GRI Bio近日宣布，其针对特发性肺纤维化（IPF）开展的二期a期临床研究获得额外积极数据。这些新发现进一步强化了候选药物GRI-0621的临床概念验证，为后续开发提供有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595754405","title":"Gri Bio, Inc.盘中异动 早盘股价大跌5.40%报0.261美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595754405","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595754405?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:59","pubTimestamp":1767020363,"startTime":"0","endTime":"0","summary":"北京时间2025年12月29日22时59分，Gri Bio, Inc.股票出现异动，股价急速下挫5.40%。截至发稿，该股报0.261美元/股，成交量95.7656万股，换手率16.31%，振幅9.75%。Gri Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.28%。Gri Bio, Inc.公司简介：GRI Bio Inc是一家临床阶段的生物技术公司，专注于发现、开发和商业化针对与免疫反应失调相关的严重疾病的疗法，这些疾病包括炎症、纤维化和自身免疫性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229225924a6dd918f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229225924a6dd918f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GRI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193690720","title":"GRI Bio Inc：第二阶段2a研究达到了次要终点，并显示胶原蛋白代谢标志物的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1193690720","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193690720?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:28","pubTimestamp":1765402089,"startTime":"0","endTime":"0","summary":"GRI Bio Inc：第二阶段2a研究达到了次要终点，并显示胶原蛋白代谢标志物的改善","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172310436","title":"GRI Bio公布特发性肺纤维化（“IPF”）II期2a研究的积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1172310436","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172310436?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:06","pubTimestamp":1765400771,"startTime":"0","endTime":"0","summary":"GRI Bio公布特发性肺纤维化（“IPF”）II期2a研究的积极顶线数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197256579","title":"GRI Bio Inc - 试验达到主要终点及某些次要终点；GRI-0621 耐受性良好 - SEC 备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1197256579","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197256579?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:14","pubTimestamp":1765199651,"startTime":"0","endTime":"0","summary":"GRI Bio Inc - 试验达到主要终点及某些次要终点；GRI-0621 耐受性良好 - SEC 备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109567142","title":"GRI Bio Inc - 接收特发性肺纤维化2a期临床试验的初步数据 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1109567142","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109567142?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:13","pubTimestamp":1765199624,"startTime":"0","endTime":"0","summary":"GRI Bio Inc - 接收特发性肺纤维化2a期临床试验的初步数据 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589812824","title":"我们找到了离“商业向善”最近的55家公司丨2025“可持续品牌典范”榜单公示","url":"https://stock-news.laohu8.com/highlight/detail?id=2589812824","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589812824?lang=zh_cn&edition=full","pubTime":"2025-12-06 21:31","pubTimestamp":1765027860,"startTime":"0","endTime":"0","summary":"历经两个月的公开征集与专业评审后，2025“可持续品牌典范”榜单已于近日正式揭晓。需要指出的是，本次评选中也有部分在ESG领域内享有声誉的企业未能上榜。虎嗅ESG承诺将持续倾听各界声音，认真总结经验，在明年的评选机制、流程设计与考察维度上进一步优化，努力呈现一份更公正、更全面、更具参考价值的可持续品牌典范榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656136076&idx=3&sn=d6e34518a3d5cf8bbe5baa9a07aad973&chksm=673dfea6eb2e31c39b6e90501da70e33ccad93d9130b0d6cfdbf3bb32bbbae849ecb0abd6bff&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4139","GRI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502792884","title":"巴斯夫MDI在东盟和南亚地区提价 每吨售价提高300美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502792884","media":"慧聪化工网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502792884?lang=zh_cn&edition=full","pubTime":"2025-01-10 14:11","pubTimestamp":1736489460,"startTime":"0","endTime":"0","summary":"慧正资讯，巴斯夫宣布自1月7日起，对其MDI在东盟地区和南亚地区进行提价，本次提价幅度为300美元/吨。巴斯夫称，此次提价的原因是物流运输、能源和监管成本的持续增长，为维持正常运营做出的必要提价。在功能性化学品领域，海名斯在2024年12月宣布将在2025年1月15日起，执行提价后的销售价格，以此应对通胀带来的成本增加。阳明海运计划上调综合费率附加费，美西和美东每40英尺集装箱的涨幅均约为2000美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-10/doc-ineeniac5682031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4575","BK4139","BK4007","BK4150","MSC","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491502879","title":"聚焦上市公司可持续发展报告“双重重要性” 需厘清编制过程中的“因为-所以”","url":"https://stock-news.laohu8.com/highlight/detail?id=2491502879","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491502879?lang=zh_cn&edition=full","pubTime":"2024-12-15 22:18","pubTimestamp":1734272280,"startTime":"0","endTime":"0","summary":"　　年关将至，上市公司新一轮的可持续发展报告披露工作启动在即。11月，三大交易所发布《可持续发展报告编制》，其中一个重大工作内容便是提出了“双重重要性”的识别、分析和披露的要求。本文结合两大重要性的发展、一揽子配套制度，以及欧盟《可持续发展报告准则》和我国三大交易所《可持续发展报告编制》中对“双重重要性”的关注，试图厘清在可持续发展报告编制过程中的“因为-所以”。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-12-15/doc-inczqiim3309007.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-15/doc-inczqiim3309007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ESG","BK4007","BK4139","GRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2478398345","title":"新股消息 | 科望医药集团拟港股IPO 证监会备案状态为“补充材料“","url":"https://stock-news.laohu8.com/highlight/detail?id=2478398345","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478398345?lang=zh_cn&edition=full","pubTime":"2024-10-25 19:20","pubTimestamp":1729855254,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月25日，中国证监会发布《境内企业境外发行证券和上市备案情况表》，其中，科望医药集团在中国证监会上市备案状态为\"补充材料\"。招股书显示，科望医药集团是一家于2017年成立的处于临床阶段的生物医药公司，致力于全球范围内利用新一代疗法创新肿瘤治疗。财务方面，于2022年、2023年，科望医药集团研发成本分别约为3.51亿元、1.08亿元人民币;同期年内亏损及全面亏损总额分别约为7.71亿元、8.53亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","YANG","HSCEI","GRI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gribio.com","stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":-0.078},{"period":"3month","weight":-0.1625},{"period":"6month","weight":-0.9665},{"period":"1year","weight":-0.9439},{"period":"ytd","weight":-0.7091}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GRI Bio, Inc.于2018年1月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对与失调的免疫反应相关疾病的疗法。其主要候选产品GRI-0621是一种正在开发的iNKT细胞口服抑制剂，用于治疗特发性肺纤维化和其他严重的炎症和纤维化疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.388047},{"month":2,"riseRate":0,"avgChangeRate":-0.328833},{"month":3,"riseRate":0,"avgChangeRate":-0.249505},{"month":4,"riseRate":0,"avgChangeRate":-0.305171},{"month":5,"riseRate":0,"avgChangeRate":-0.187187},{"month":6,"riseRate":0,"avgChangeRate":-0.217093},{"month":7,"riseRate":0,"avgChangeRate":-0.254878},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.299007},{"month":9,"riseRate":0.666667,"avgChangeRate":0.137892},{"month":10,"riseRate":0.333333,"avgChangeRate":0.348158},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.181412},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.344856}],"exchange":"NASDAQ","name":"GRI BIO INC","nameEN":"GRI BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRI BIO INC(GRI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供GRI BIO INC(GRI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"GRI BIO INC,GRI,GRI BIO INC股票,GRI BIO INC股票老虎,GRI BIO INC股票老虎国际,GRI BIO INC行情,GRI BIO INC股票行情,GRI BIO INC股价,GRI BIO INC股市,GRI BIO INC股票价格,GRI BIO INC股票交易,GRI BIO INC股票购买,GRI BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRI BIO INC(GRI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供GRI BIO INC(GRI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}